Nuclear factor-κB and chemoresistance: How intertwined are they?

Drug Resistance in Cancer Cells

Volumn , Issue , 2009, Pages 177-208

  Kunnumakkara, Ajaikumar B ^a   Anand, Preetha ^a   Aggarwal, Bharat B ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Apoptosis inhibitor proteins; Cell adhesion; Cell cycle; Chemoresistance; Chemosensitization; Multidrug resistance; Nuclear factor B

Indexed keywords

EID: 84900172737     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-89445-4_8     Document Type: Chapter

References (177)

1. Abdel-Latif, M. M., O'Riordan, J., Windle, H. J., Carton, E., Ravi, N., Kelleher, D., and Reynolds, J. V. 2004. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann. Surg. 4:491-500.
2. Aggarwal, B. B., Schwarz, L., Hogan, M. E., and Rando, R. F. 1996. Triple helix-forming oligodeoxyribonucleotides targeted to the human tumor necrosis factor (TNF) gene inhibit TNF production and block the TNF-dependent growth of human glioblastoma tumor cells. Cancer Res. 56:5156-5164.
3. Aggarwal, B. B., Sethi, G., Ahn, K. S., Sandur, S. K., Pandey, M. K., Kunnumakkara, A. B., Sung, B., and Ichikawa, H. 2006a. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci. 1091:151-169.
4. Aggarwal, B. B., Sethi, G., Nair, A., and Ichikawa, H. 2006b. Nuclear factor-B: a Holy Grail in cancer prevention and therapy. Curr. Signal Transduct. Ther. 1:25-52.
5. Aggarwal, B. B., Shishodia, S., Sandur, S. K., Pandey, M. K., and Sethi, G. 2006c. Inflammation and cancer: how hot is the link? Biochem. Pharmacol. 72:1605-1621.
6. Aggarwal, S., Ichikawa, H., Takada, Y., Sandur, S. K., Shishodia, S., and Aggarwal, B. B. 2006d. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol. Pharmacol. 1:195-206.
7. Aggarwal, B. B., Shishodia, S., Takada, Y., Banerjee, S., Newman, R. A., Bueso-Ramos, C. E., and Price, J. E. 2005. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin. Cancer Res. 11:7490-7498.
8. Aggarwal, B. B. 2004. Nuclear factor-kappaB: the enemy within. Cancer Cell 6:203-208.
9. Ahn, K. S., and Aggarwal, B. B. 2005. Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann. N. Y. Acad. Sci. 1056:218-233.
10. Albihn, A., Mo, H., Yang, Y., and Henriksson, M. 2007. Camptothecin-induced apoptosis is enhanced by Myc and involves PKCdelta signaling. Int. J. Cancer. 121:1821-1829.
11. Andriollo, M., Favier, A., and Guiraud, P. 2003. Adriamycin activates NF-kappaB in human lung carcinoma cells by IkappaBalpha degradation. Arch. Biochem. Biophys. 413:75-82.
12. Angileri, F. F., Aguennouz, M., Conti, A., La Torre, D., Cardali, S., Crupi, R., Tomasello, C., Germanò, A., Vita, G., and Tomasello, F. 2008. Nuclear factor-kappaB activation and differential expression of survivin and Bcl-2 in human grade 2-4 astrocytomas. Cancer 112:2258-2266.
13. Anuchapreeda, S., Leechanachai, P., Smith, M. M., Ambudkar, S. V., and Limtrakul, P. N. 2002. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem. Pharmacol. 64:573-582.
14. Aoudjit, F., and Vuori, K. 2001. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene. 20:4995-5004.
15. Arango, D., Mariadason, J. M., Wilson, A. J., Yang, W., Corner, G. A., Nicholas, C., Aranes, M. J., and Augenlicht, L. H. 2003. c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis. Br. J. Cancer 89:1757-1765.
16. Ashikawa, K., Shishodia, S., Fokt, I., Priebe, W., and Aggarwal, B. B. 2004. Evidence that activation of nuclear factor-kappaB is essential for the cytotoxic effects of doxorubicin and its analogues. Biochem. Pharmacol. 67:353-364.
17. Baby, J., Pickering, B. F., Vashisht Gopal, Y. N., and Van Dyke, M. W. 2007. Constitutive and inducible nuclear factor-kappaB in immortalized normal human bronchial epithelial and nonsmall cell lung cancer cell lines. Cancer Lett. 1:85-94.
18. Banerjee, S., Zhang, Y., Wang, Z., Che, M., Chiao, P. J., Abbruzzese, J. L., and Sarkar, F. H. 2007. In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. Int. J. Cancer 120:906-917.
19. Banerjee, S., Zhang, Y., Ali, S., Bhuiyan, M., Wang, Z., Chiao, P. J., Philip, P. A., Abbruzzese, J., and Sarkar, F. H. 2005. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res. 65:9064-9072.
20. Bargou, R. C., Emmerich, F., Krappmann, D., Bommert, K., Mapara, M. Y., Arnold, W., Royer, H. D., Grinstein, E., Greiner, A., Scheidereit, C., and Dörken, B. 1997. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J. Clin. Invest. 12:2961-2969.
21. Baron, F., Frère, P., Herens, C., Fillet, G., and Beguin, Y. 2002. Combination of non myeloablative stem cell transplantation and Imatinib in accelerated phase CML. Haematologica. 87: ECR43.
22. Beg, A. A., and Baltimore, D. 1996. An essential role for NF-kappaB in preventing TNF-alphainduced cell death. Science 274:782-784.
23. Beevers, C. S., Li, F., Liu, L., and Huang, S. 2006. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int. J. Cancer. 119:757-764.
24. Bharti, A. C., Donato, N., Singh, S., and Aggarwal, B. B. 2003. Curcumin (diferuloyl-methane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101:1053-1062.
25. Bharti, A. C., Donato, N., and Aggarwal, B. B. 2003. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J. Immunol. 171:3863-3871.
26. Bharti, A. C., Shishodia, S., Reuben,. J. M., Weber, D., Alexanian, R., Raj-Vadhan, S., Estrov, Z., Talpaz, M., and Aggarwal, B. B. 2004. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 8:3175-3184.
27. Bhat-Nakshatri, P., Sweeney, C. J., and Nakshatri, H. 2002. Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells. Oncogene. 13:2066-2078.
28. Bian, Z. M., Elner, V. M., Yoshida, A., Kunkel, S. L., and Elner, S. G. 2001. Signaling pathways for glycated human serum albumin-induced IL-8 and MCP-1 secretion in human RPE cells. Invest. Ophthalmol. Vis. Sci. 42:1660-1668.
29. Birkenkamp, K. U., Geugien, M., Schepers, H., Westra, J., Lemmink, H. H., and Vellenga, E. 2004. Constitutive NF-kappaB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway. Leukemia. 1:103-112.
30. Biswas, D. K., Dai, S. C., Cruz, A., Weiser, B., Graner, E., and Pardee, A. B. 2001. The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers. Proc. Natl. Acad. Sci. U S A. 18:10386-10391.
31. Bon, G., Folgiero, V., Bossi, G., Felicioni, L., Marchetti, A., Sacchi, A., and Falcioni, R. 2006. Loss of beta4 integrin subunit reduces the tumorigenicity of MCF7 mammary cells and causes apoptosis upon hormone deprivation. Clin. Cancer Res. 12:3280-3287.
32. Bond, M., Fabunmi, R. P., Baker, A. H., and Newby, A. C. 1998. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett. 435:29-34.
33. Bonizzi, G., Piette, J., Schoonbroodt, S., Greimers, R., Havard, L., Merville, M. P., and Bours, V. 1999. Reactive oxygen intermediate-dependent NF-kappaB activation by interleukin-1beta requires 5-lipoxygenase or NADPH oxidase activity. Mol. Cell Biol. 19:1950-1960.
34. Bottero, V., Busuttil, V., Loubat, A., Magné, N., Fischel, J. L., Milano, G., and Peyron, J. F. 2001. Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells. Cancer Res. 21:7785-7791.
35. Braun, T., Carvalho, G., Coquelle, A., Vozenin, M. C., Lepelley, P., Hirsch, F., Kiladjian, J. J., Ribrag, V., Fenaux, P., and Kroemer, G. 2006. NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 3:1156-1165.
36. Buchholz, T. A., Garg, A. K., Chakravarti, N., Aggarwal, B. B., Esteva, F. J., Kuerer, H. M., Singletary, S. E., Hortobagyi, G. N., Pusztai, L., Cristofanilli, M., and Sahin, A. A. 2005. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Clin. Cancer Res. 23:8398-8402.
37. Budunova, I. V., Perez, P., Vaden, V. R., Spiegelman, V. S., Slaga, T. J., and Jorcano, J. L. 1999. Increased expression of p50-NF-kappaB and constitutive activation of NF-kappaB transcription factors during mouse skin carcinogenesis. Oncogene. 52:7423-7431.
38. Bueso-Ramos, C. E., Rocha, F. C., Shishodia, S., Medeiros, L. J., Kantarjian, H. M., Vadhan-Raj, S., Estrov Z., Smith, T. L., Nguyen, M. H., and Aggarwal, B. B. 2004. Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia. Hum. Pathol. 2:246-253.
39. Chen, A., and Xu, J. 2005. Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. Am. J. Physiol. Gastrointest. Liver Physiol. 288:G447-456.
40. Cogswell, P. C., Guttridge, D. C., Funkhouser, W. K., and Baldwin, A. S. Jr. 2000. Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene. 9:1123-1131.
41. Collins, T., Read, M. A., Neish, A. S., Whitley, M. Z., Thanos, D., and Maniatis, T. 1995. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J. 9:899-909.
42. Cusack, J. C. Jr., Liu, R., Baldwin, A. S. Jr. 2000. Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]- carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation. Cancer Res. 9:2323-2330.
43. Dan, H. C., Cooper, M. J., Cogswell, P. C., Duncan, J. A., Ting, J. P., and Baldwin, A. S. 2008. Aktdependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev. 22:1490-1500.
44. Das, K. C., and White, C. W. 1997. Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C. J. Biol. Chem. 272:14914-14920.
45. Das, S., Ongusaha, P. P., Yang, Y. S., Park, J. M., Aaronson, S. A., and Lee, S. W. 2006. Discoidin domain receptor 1 receptor tyrosine kinase induces cyclooxygenase-2 and promotes chemoresistance through nuclear factor-kappaB pathway activation. Cancer Res. 66:8123-8130.
46. Datta, S. R., Brunet, A., and Greenberg, M. E. 1999. Cellular survival: a play in three Akts. Genes Dev. 13:2905-2927.
47. Davis, R. E., Brown, K. D., Siebenlist, U., Staudt, L. M. 2001. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 12:1861-1874.
48. Devalaraja, M. N., Wang, D. Z., Ballard, D. W., and Richmond, A. 1999. Elevated constitutive IkappaB kinase activity and IkappaB-alpha phosphorylation in Hs294T melanoma cells lead to increased basal MGSA/GRO-alpha transcription. Cancer Res. 6:1372-1377.
49. Dolcet, X., Llobet, D., Encinas, M., Pallares, J., Cabero, A., Schoenenberger, J. A., Comella, J. X., and Matias-Guiu, X. 2006. Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants. J. Biol. Chem. 281:22118-22130.
50. Du, J., Chen, G. G., Vlantis, A. C., Xu, H., Tsang, R. K., and Van Hasselt, A. C. 2003. The nuclear localization of NFkappaB and p53 is positively correlated with HPV16 E7 level in laryngeal squamous cell carcinoma. J. Histochem. Cytochem. 4:533-539.
51. Erl, W., Hansson, G. K., De Martin, R., Draude, G., Weber, K. S., and Weber, C. 1999. Nuclear factor-kappa B regulates induction of apoptosis and inhibitor of apoptosis protein-1 expression in vascular smooth muscle cells. Circ. Res. 84:668-677.
52. Estrov, Z., Thall, P. F., Talpaz, M., Estey, E. H., Kantarjian, H. M., Andreeff, M., Harris, D., Van, Q., Walterscheid, M., and Kornblau, S. M. 1998. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood 92:3090-3097.
53. Fahy, B. N., Schlieman, M. G., Virudachalam, S., and Bold, R. J. 2004. Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer. J. Am. Coll. Surg. 4:591-599.
54. Feinman, R., Koury, J., Thames, M., Barlogie, B., Epstein, J., and Siegel, D. S. 1999. Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 93:3044-3052.
55. Feinman, R., Siegel, D. S., and Berenson, J. 2004. Regulation of NF-kB in multiple myeloma: therapeutic implications. Clin. Adv. Hematol. Oncol. 3:162-166.
56. Fingar, D. C., and Blenis, J. 2004. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene. 23:3151-3171.
57. Flynn, V. Jr., Ramanitharan, A., Moparty, K., Davis, R., Sikka, S., Agrawal, K. C., and Abdel-Mageed, A. B. 2003. Adenovirus-mediated inhibition of NF-kappaB confers chemosensitization and apoptosis in prostate cancer cells. Int. J. Oncol. 23:317-323.
58. Foehr, E. D., Lin, X., O'Mahony, A., Geleziunas, R., Bradshaw, R. A., and Greene, W. C. 2000. NFkappa B signaling promotes both cell survival and neurite process formation in nerve growth factor-stimulated PC12 cells. J. Neurosci. 20:7556-7563.
59. Fok, J. Y., Ekmekcioglu, S., and Mehta, K. 2006. Implications of tissue transglutaminase expression in malignant melanoma. Mol. Cancer Ther. 5:1493-1503.
60. Fujioka, S., Sclabas, G. M., Schmidt, C., Frederick, W. A., Dong, Q. G., Abbruzzese, J. L., Evans, D. B., Baker, C., and Chiao, P. J. 2003. Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin. Cancer Res. 1:346-354.
61. Fulda, S., Meyer, E., Friesen, C., Susinm S. A., Kroemer, G., and Debatin, K. M. 2001. Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene. 20:1063-1075.
62. Funato, T., Kozawa, K., Kaku, M., and Sasaki, T. 2001. Modification of the sensitivity to cisplatin with c-myc over-expression or down-regulation in colon cancer cells. Anticancer Drugs 10:829-834.
63. Giri, D. K., and Aggarwal, B. B. 1998. Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells: autocrine role of tumor necrosis factor and reactive oxygen intermediates. J. Biol. Chem. 273:14008-14014.
64. Gradilone, A., Silvestri, I., Scarpa, S., Morrone, S., Gandini, O., Pulcinelli, F. M., Gianni, W., Frati, L., Aglianò, A. M., and Gazzaniga, P. 2007. Failure of apoptosis and activation on NFkappaB by celecoxib and aspirin in lung cancer cell lines. Oncol. Rep. 17:823-828.
65. Godin-Heymann, N., Ulkus, L., Brannigan, B. W., McDermott, U., Lamb, J., Maheswaran, S., Settleman, J., Haber, D. A. 2008. The T790M " gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol. Cancer Ther. 4:874-879.
66. Griffin, J. D. 2001. Leukemia stem cells and constitutive activation of NF-kappaB. Blood 98:2291.
67. Gukovsky, I., Reyes, C. N., Vaquero, E. C., Gukovskaya, A. S., and Pandol, S. J. 2003. Curcumin ameliorates ethanol and nonethanol experimental pancreatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 284:G85-G95.
68. Guzman, M. L., Neering, S. J., Upchurch, D., Grimes, B., Howard, D. S., Rizzieri, D. A., Luger, S. M., and Jordan, C. T. 2001. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 8:2301-2307.
69. Habib, A. A., Chatterjee, S., Park, S. K., Ratan, R. R., Lefebvre, S., and Vartanian T. 2001. The epidermal growth factor receptor engages receptor interacting protein and nuclear factor-kappa B (NF-kappa B)-inducing kinase to activate NF-kappa B: identification of a novel receptortyrosine kinase signalosome. J. Biol. Chem. 276:8865-8874.
70. Hacker, H., and Karin, M. 2006. Regulation and function of IKK and IKK-related kinases. Sci. STKE 2006: re13.
71. Han, J. A., and Park, S. C. 1999. Reduction of transglutaminase 2 expression is associated with an induction of drug sensitivity in the PC-14 human lung cancer cell line. J. Cancer Res. Clin. Oncol. 2:89-95.
72. Hazlehurst, L. A., Valkov, N., Wisner, L., Storey, J. A., Boulware, D., Sullivan, D. M., and Dalton, W. S. 2001. Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood 98:1897-1903.
73. Helbig, G., Christopherson, K. W.2nd., Bhat-Nakshatri, P., Kumar, S, Kishimoto, H., Miller, K. D., Broxmeyer, H. E., and Nakshatri, H. 2003. NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J. Biol. Chem. 278:21631-21638.
74. Higgins, K. A., Perez, J. R., Coleman, T. A., Dorshkind, K., McComas, W. A., Sarmiento, U. M., Rosen, C. A., and Narayanan, R. 1993. Antisense inhibition of the p65 subunit of NF-kappa B blocks tumorigenicity and causes tumor regression. Proc. Natl. Acad. Sci. U S A. 21:9901-9905.
75. Ho, W. C., Dickson, K. M., and Barker, P. A. 2005. Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-kappaB-dependent transcription in cancer cells. Cancer Res. 65:4273-4281.
76. Hönemann, D., Chatterjee, M., Savino, R., Bommert, K., Burger, R., Gramatzki, M., Dörken, B., and Bargou, R. C. 2001. The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells. Int. J. Cancer. 93:674-680.
77. Hong, J., Bose, M., Ju, J., Ryu, J. H., Chen, X., Sang, S., Lee, M. J., and Yang, C. S. 2004. Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A (2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis. 25:1671-1679.
78. Hong, R. L., Spohn, W. H., and Hung, M. C. 1999. Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. Clin. Cancer Res. 5:1884-1891.
79. Huang, S., De Guzman, A., Bucana, C. D., and Fidler, I. J. 2000a. Level of interleukin-8 expression by metastatic human melanoma cells directly correlates with constitutive NF-kappaB activity. Cytokines Cell Mol. Ther. 1:9-17.
80. Huang, S., Robinson, J. B., Deguzman, A., Bucana, C. D., and Fidler, I. J. 2000b. Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res. 19:5334-5339.
81. Hwang, S., and Ding, A. 1995. Activation of NF-kappa B in murine macrophages by taxol. Cancer Biochem. Biophys. 4:265-272.
82. Izzo, J. G., Correa, A. M., Wu, T. T., Malhotra, U., Chao, C. K., Luthra, R., Ensor, J., Dekovich, A., Liao, Z., Hittelman, W. N., Aggarwal, B. B., and Ajani, J. A. 2006. Pretherapy nuclear factorkappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol. Cancer Ther. 11:2844-2850.
83. Jackson-Bernitsas, D. G., Ichikawa, H., Takada, Y., Myers, J. N., Lin, X. L., Darnay, B. G., Chaturvedi, M. M., and Aggarwal, B. B. 2007. Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kappaB activation and proliferation in human head and neck squamous cell carcinoma. Oncogene. 10:1385-1397.
84. Junttila, M. R., and Westermarck, J. 2008. Mechanisms of MYC stabilization in human malignancies. Cell Cycle. 7:592-596.
85. Kakar, S. S., and Roy, D. 1994. Curcumin inhibits TPA induced expression of c-fos, c-jun and c-myc proto-oncogenes messenger RNAs in mouse skin. Cancer Lett. 87:85-89.
86. Kamat, A. M., Sethi, G., and Aggarwal, B. B. 2007. Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cells. Mol. Cancer Ther. 3:1022-1030.
87. Kane, L. P., Shapiro, V. S., Stokoe, D., and Weiss, A. 1999. Induction of NF-kappaB by the Akt/PKB kinase. Curr. Biol. 9:601-604.
88. Kang, Y. C., Kim, K. M., Lee, K. S., Namkoong, S., Lee, S. J., Han, J. A., Jeoung, D., Ha, K. S., Kwon, Y. G., and Kim, Y. M. 2004. Serum bioactive lysophospholipids prevent TRAIL-induced apoptosis via PI3K/Akt-dependent cFLIP expression and Bad phosphorylation. Cell Death Differ. 11:1287-1298.
89. Kato, T., Duffey, D. C., Ondrey, F. G., Dong, G., Chen, Z., Cook, J. A, Mitchell, J. B., and Van Waes, C. 2000. Cisplatin and radiation sensitivity in human head and neck squamous carcinomas are independently modulated by glutathione and transcription factor NF-kappaB. Head Neck 22:748-759.
90. Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms J., and Waterfield, M. D. 2001. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Ann. Rev. Cell Dev. Biol. 17:615-675.
91. Kim, D. S., Park, S. S., Nam, B. H., Kim, I. H., and Kim, S. Y. 2006. Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. Cancer Res. 66:10936-10943.
92. Kordes, U., Krappmann, D., Heissmeyer, V., Ludwig, W. D., and Scheidereit, C. 2000. Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia. 14:399-402.
93. Kornmann, M., Danenberg, K. D., Arber, N., Beger, H. G., Danenberg, P. V., and Korc, M. 1999. Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. Cancer Res. 59:3505-3511.
94. Kreuz, S., Siegmund, D., Scheurich, P., and Wajant, H. 2001. NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol. Cell Biol. 21:3964-3973.
95. Kumar, A., Dhawan, S., Hardegen, N. J., and Aggarwal, B. B. 1998. Curcumin (Diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-kappaB activation. Biochem. Pharmacol. 55:775-783.
96. Kunnumakkara, A. B., Guha, S., Krishnan, S., Diagaradjane, P., Gelovani, J., and Aggarwal, B. B. 2007. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factorkappaB-regulated gene products. Cancer Res. 67:3853-3861.
97. Kuo, M. T., Liu, Z., Wei, Y., Lin-Lee, Y. C., Tatebe, S., Mills, G. B., and Unate, H. 2002. Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling. Oncogene. 13:1945-1954.
98. Ledoux, S., Yang, R., Friedlander, G., and Laouari, D. 2003. Glucose depletion enhances Pglycoprotein expression in hepatoma cells: role of endoplasmic reticulum stress response. Cancer Res. 63:7284-7290.
99. Lee, B. L., Lee, H. S., Jung, J., Cho, S. J., Chung, H. Y., Kim, W. H., Jin, Y. W., Kim, C. S., and Nam, S. Y. 2005. Nuclear factor-kappaB activation correlates with better prognosis and Akt activation in human gastric cancer. Clin. Cancer Res. 7:2518-2525.
100. Lee, T. K., Poon, R. T., Wo, J. Y., Ma, S., Guan, X. Y., Myers, J. N., Altevogt, P., and Yuen, A. P. 2007. Lupeol suppresses cisplatin-induced nuclear factor-kappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model. Cancer Res. 67:8800-8809.
101. Li, L., Ahmed, B., Mehta, K., and Kurzrock, R. 2007. Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol. Cancer Ther. 4:1276-1282.
102. Li, Q. X., Zhao, J., Liu, J. Y., Jia, L. T., Huang, H. Y., Xu, Y. M., Zhang, Y., Zhang, R., Wang, C. J., Yao, L. B., Chen, S. Y., and Yang, A. G. 2006. Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers. Cancer Biol. Ther. 5:860-866.
103. Lin, Y. G., Kunnumakkara, A. B., Nair, A., Merritt, W. M., Han, L. Y., Armaiz-Pena, G. N., Kamat, A. A., Spannuth, W. A., Gershenson, D. M., Lutgendorf, S. K., Aggarwal, B. B., and Sood, A. K. 2007. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res. 11:3423-3430.
104. Lind, D. S., Hochwald, S. N., Malaty, J., Rekkas, S., Hebig, P., Mishra, G., Moldawer, L. L., Copeland, E. M. 3rd., and Mackay, S. 2001. Nuclear factor-kappa B is upregulated in colorectal cancer. Surgery 2:363-269.
105. Liu, J. Y., Lin, S. J., and Lin, J. K. 1993. Inhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradecanoyl-phorbol-13- acetate in NIH 3T3 cells. Carcinogenesis. 14:857-861.
106. Ludwig, L., Kessler, H., Wagner, M., Hoang-Vu, C., Dralle, H., Adler, G., Böhm, B. O., and Schmid, R. M. 2001. Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation. Cancer Res. 11:4526-4535.
107. Mabuchi, S., Ohmichi, M., Kimura, A., Hisamoto, K., Hayakawa, J., Nishio, Y., Adachi, K., Takahashi, K., Arimoto-Ishida, E., Nakatsuji, Y., Tasaka, K. and Murata, Y. 2002. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J. Biol. Chem. 277:33490-33500.
108. Mackenzie, G. G., Queisser, N., Wolfson, M. L., Fraga, C. G., Adamo, A. M., and Oteiza, P. I. 2008. Curcumin induces cell-arrest and apoptosis in association with the inhibition of constitutively active NF-kappaB and STAT3 pathways in Hodgkin's lymphoma cells. Int. J. Cancer. 123:56-65.
109. Mathas, S., Jöhrens, K., Joos, S., Lietz, A., Hummel, F., Janz M., Jundt. F., Anagnostopoulos, I., Bommert, K., Lichter, P., Stein, H., Scheidereit, C., and Dörken, B. 2005. Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas. Blood 13:4287-4293.
110. Mann, A. P., Verma, A., Sethi, G., Manavathi, B., Wang, H., Fok, J. Y., Kunnumakkara, A. B., Kumar, R., Aggarwal, B. B., and Mehta, K. 2006. Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res. 66:8788-8795.
111. Mehta, K. 1994. High levels of transglutaminase expression in doxorubicin-resistant human breast carcinoma cells. Int. J. Cancer. 58:400-406.
112. Mehta, K., Pantazis, P., McQueen, T., and Aggarwal. B. B. 1997. Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines. Anticancer Drugs. 8:470-481.
113. Mehta, K., Fok, J., Miller, F. R., Koul, D., and Sahin, A. A. 2004. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res. 10:8068-8076.
114. Merritt, J. E., Sullivan, J. A., Drew, L., Khan, A., Wilson, K., Mulqueen, M., Harris, W., Bradshaw, D., Hill, C. H., Rumsby, M., and Warr, R. 1999. The bisindolylmaleimide protein kinase C inhibitor, Ro 32-2241, reverses multidrug resistance in KB tumour cells. Cancer Chemother. Pharmacol. 43:371-378.
115. Moragoda, L., Jaszewski, R., and Majumdar, A. P. 2001. Curcumin induced modulation of cell cycle and apoptosis in gastric and colon cancer cells. Anticancer Res. 21:873-878.
116. Mukhopadhyay, A., Banerjee, S., Stafford, L. J., Xia, C., Liu, M., and Aggarwal, B. B. 2002. Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene. 21:8852-8861.
117. Mukhopadhyay, A., Bueso-Ramos, C., Chatterjee, D., Pantazis, P., and Aggarwal, B. B. 2001. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene. 20:7597-7609.
118. Nadiminty, N., Lou, W., Lee, S. O., Lin, X., Trump, D. L., and Gao, A. C. 2006. Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylation. Proc. Natl. Acad. Sci. U S A. 103:7264-7269.
119. Nakayama, H., Ikebe, T., Beppu, M., and Shirasuna, K. 2001. High expression levels of nuclear factor kappaB, IkappaB kinase alpha and Akt kinase in squamous cell carcinoma of the oral cavity. Cancer 12:3037-3044.
120. Nakshatri, H., Bhat-Nakshatri, P., Martin, D. A., Goulet, R. J. Jr., and Sledge, G. W. Jr. 1997. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol. Cell Biol. 17:3629-3639.
121. Ng, C. P., Zisman, A., and Bonavida, B. 2002. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Prostate 53:286-299.
122. Novak, U., Cocks, B. G., and Hamilton, J. A. 1991. A labile repressor acts through the NFkB-like binding sites of the human urokinase gene. Nucleic Acids. Res. 19:3389-3393.
123. Ondrey, F. G., Dong, G., Sunwoo, J., Chen, Z., Wolf, J. S., Crowl-Bancroft, C. V., Mukaida, N., and Van Waes, C. 1999. Constitutive activation of transcription factors NF-(kappa) B, AP-1, and NFIL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Mol. Carcinog. 2:119-129.
124. Palayoor, S. T., Youmell, M. Y., Calderwood, S. K., Coleman, C. N., and Price, B. D. 1999. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene. 18:7389-7394.
125. Park, C. C., Zhang, H., Pallavicini, M., Gray, J. W., Baehner, F., Park, C. J., and Bissell, M. J. 2006. Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res. 66:1526-1535.
126. Patel, N. M., Nozaki, S., Shortle, N. H., Bhat-Nakshatri, P., Newton, T. R., Rice, S., Gelfanov, V., Boswell, S. H., Goulet, R. J. Jr., Sledge, G. W. Jr., and Nakshatri, H. 2000. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha superrepressor and parthenolide. Oncogene. 19:4159-4169.
127. Pham, L. V., Tamayo, A. T., Yoshimura, L. C., Lo, P., and Ford, R. J. 2003. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J. Immunol. 1:88-95.
128. Pianetti, S., Arsura, M., Romieu-Mourez, R., Coffey, R. J., and Sonenshein, G. E. 2001. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene. 20:1287-1299.
129. Piret, B., and Piette, J. 1996. Topoisomerase poisons activate the transcription factor NF-kappaB in ACH-2 and CEM cells. Nucleic Acids Res. 24:4242-4248.
130. Pollet, I., Opina, C. J., Zimmerman, C., Leong, K. G., Wong, F., and Karsan, A. 2003. Bacterial lipopolysaccharide directly induces angiogenesis through TRAF6-mediated activation of NFkappaB and c-Jun. N-terminal kinase. Blood 102:1740-1742.
131. Qiao, L., Zhang, H., Yu, J., Francisco, R., Dent, P., Ebert, M. P., Röcken, C., and Farrell, G. 2006 Constitutive activation of NF-kappaB in human hepatocellular carcinoma: evidence of a cytoprotective role. Hum. Gene Ther. 3:280-290.
132. Rath, P. C. 2005. Relationship between constitutive nuclear factor-kappaB (NF-kappaB) and inhibitor kappaB-alpha (IkappaB-alpha) in an interferon-alpha-sensitive human Burkitt lymphoma cell line. Biochim. Biophys. Acta. 3:253-263.
133. Ray, S., Chattopadhyay, N., Mitra, A., Siddiqi, M., and Chatterjee, A. 2003. Curcumin exhibits antimetastatic properties by modulating integrin receptors, collagenase activity, and expression of Nm23 and E-cadherin. J Environ Pathol Toxicol Oncol. 22:49-58.
134. Romashkova, J. A., and Makarov, S. S. 1999. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401:86-90.
135. Sasaki, N., Morisaki, T., Hashizume, K., Yao, T., Tsuneyoshi, M., Noshiro, H., Nakamura, K., Yamanaka, T., Uchiyama, A., Tanaka, M., and Katano, M. 2001. Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res. 12:4136-4142.
136. Schmidmaier, R., Mörsdorf, K., Baumann, P., Emmerich, B., and Meinhardt, G. 2006. Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo. Int. J. Biol. Markers 21:218-222.
137. Schroeder, C. P., Yang, P., Newman, R. A., and Lotan, R. 2007. Simultaneous inhibition of COX-2 and 5-LOX activities augments growth arrest and
138. Selvendiran, K., Bratasz, A., Tong, L., Ignarro, L. J., and Kuppusamy, P. 2008. NCX-4016, a nitroderivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts. Cell Cycle 7:81-88.
139. Seppänen, M., and Vihko, K. K. 2000. Activation of transcription factor NF-kappaB by growth inhibitory cytokines in vulvar carcinoma cells. Immunol Lett. 74:103-109.
140. Sethi, G., and Aggarwal, B. B. 2006. Role of NF-B and NF-B-regulated gene products in chemoresistance and radioresistance. Curr. Cancer Ther. Rev. 2:115-125.
141. Sethi, G., Ahn, K. S., Chaturvedi, M. M., and Aggarwal, B. B. 2007. Epidermal growth factor (EGF) activates nuclear factor-kappaB through IkappaBalpha kinase-independent but EGF receptorkinase dependent tyrosine 42 phosphorylation of IkappaBalpha. Oncogene. 26:7324-7332.
142. Shattuck-Brandt, R. L., and Richmond, A. 1997. Enhanced degradation of I-kappaB alpha contributes to endogenous activation of NF-kappaB in Hs294T melanoma cells. Cancer Res. 57:3032-3039.
143. Shinohara, Y., Iwasaki, H., Ota, N., Nakajima, T., Kodaira, M., Kajita, M., Shiba, T., and Emi, M. 2001. Novel single nucleotide polymorphisms of the human nuclear factor kappa-B 2 gene identified by sequencing the entire gene. J. Hum. Genet. 1:50-51.
144. Shishodia, S., Amin, H. M., Lai, R., and Aggarwal, B. B. 2005. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem. Pharmacol. 5:700-713.
145. Shishodia, S., and Aggarwal, B. B. 2004. Nuclear factor-kappaB activation mediates cellular transformation, proliferation, invasion angiogenesis and metastasis of cancer. Cancer Treat. Res. 119:139-173.
146. Shishodia, S., and Aggarwal, B. B. 2002. Nuclear factor-kappaB activation: a question of life or death. J. Biochem. Mol. Biol. 35:28-40.
147. Singh, B., Cook, K. R., Vincent, L., Hall, C. S., Berry, J. A., Multani, A. S., and Lucci, A. 2008. Cyclooxygenase-2 induces genomic instability, BCL2 expression, doxorubicin resistance, and altered cancer-initiating cell phenotype in MCF7 breast cancer cells. J. Surg. Res. 147:240-246.
148. Singh, S., and Aggarwal, B. B. 1995. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected] J. Biol. Chem. 270:24995-5000.
149. Song, Y. C., Xia, W., Jiang, J. H., and Wang, Q. D. 2005. [Reversal of multidrug resistance in drugresistant cell line EAC/ADR by cepharanthine hydrochloride and its mechanism] Yao Xue Xue Bao. 40:204-207.
150. Spiekermann, K., Dirschinger, R. J., Schwab, R., Bagrintseva, K., Faber, F., Buske, C., Schnittger, S., Kelly, L. M., Gilliland, D. G., and Hiddemann, W. 2003. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood 101:1494-1504.
151. Sovak, M. A., Bellas, R. E., Kim, D. W., Zanieski, G. J., Rogers, A. E., Traish, A. M., and Sonenshein, G. E. 1997. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest. 12:2952-2960.
152. Squires, M. S., Hudson, E. A., Howells, L., Sale, S., Houghton, C. E., Jones, J. L., Fox, L. H., Dickens, M., Prigent, S. A., and Manson, M. M. 2003. Relevance of mitogen activated protein kinase (MAPK) and phosphatidylinositol-3- kinase/protein kinase B (PI3K/PKB) pathways to induction of apoptosis by curcumin in breast cells. Biochem. Pharmacol. 65:361-376.
153. Stehlik, C., De Martin, R., Kumabashiri, I., Schmid, J. A., Binder, B. R., and Lipp, J. 1998. Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J. Exp. Med. 188:211-216.
154. Tai, D. I., Tsai, S. L., Chang, Y. H., Huang, S. N., Chen, T. C., Chang, K. S., and Liaw, Y. F. 2000. Constitutive activation of nuclear factor kappaB in hepatocellular carcinoma. Cancer. 11:2274-2281.
155. Tamatani, T., Azuma, M., Aota, K., Yamashita, T., Bando, T., and Sato, M. 2001. Enhanced IkappaB kinase activity is responsible for the augmented activity of NF-kappaB in human head and neck carcinoma cells. Cancer Lett. 2:165-172.
156. Tamm, I., Kornblau, S. M., Segall, H., Krajewski, S., Welsh, K., Kitada, S., Scudiero, D. A., Tudor, G., Qui, Y. H., Monks, A., Andreeff, M., and Reed, J. C. 2000. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin. Cancer Res. 6:1796-1803.
157. Tang, X., Liu, D., Shishodia, S., Ozburn, N., Behrens, C., Lee, J. J., Hong, W. K., Aggarwal, B. B., and Wistuba, I. I. 2006. Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer. 107:2637-2646.
158. Tomita, M., Kawakami, H., Uchihara, J. N., Okudaira, T., Masuda, M., Takasu, N., Matsuda, T., Ohta, T., Tanaka, Y., Ohshiro, K., and Mori, N. 2006. Curcumin (diferuloylmethane) inhibits constitutive active NF-kappaB, leading to suppression of cell growth of human T-cell leukemia virus type I-infected T-cell lines and primary adult T-cell leukemia cells. Int. J. Cancer. 118:765-772.
159. Uetsuka, H., Haisa, M., Kimura, M., Gunduz, M., Kaneda, Y., Ohkawa, T., Takaoka, M., Murata, T., Nobuhisa, T., Yamatsuji, T., Matsuoka, J., Tanaka, N., and Naomoto, Y. 2003. Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. Exp. Cell Res. 289:27-35.
160. Um, J. H., Kang, C. D., Lee, B. G., Kim, D. W., Chung, B. S., and Kim, S. H. 2001. Increased and correlated nuclear factor-kappa B and Ku autoantigen activities are associated with development of multidrug resistance. Oncogene. 20:6048-6056.
161. Van De Stolpe, A., Caldenhoven, E., Stade, B. G., Koenderman, L., Raaijmakers, J. A., Johnson, J. P., and Van Der Saag, P. T. 1994. 12-O-tetradecanoyl-phorbol-13-acetate- and tumor necrosis factor alpha-mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone: functional analysis of the human intercellular adhesion molecular-1 promoter. J. Biol. Chem. 269:6185-6192.
162. Van Laere, S., Van Der Auwera, I., Van Den Eynden, G. G., Fox, S. B., Bianch, I. F., Harris, A. L., Van Dam, P., Van Marck, E. A., Vermeulen, P. B., and Dirix, L. Y. 2005. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Res. Treat. 3:237-246.
163. Verma, A., Wang, H., Manavathi, B., Fok, J. Y., Mann, A. P., Kumar, R., and Mehta, K. 2006. Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res. 21:10525-10533.
164. Visconti, R., Cerutti, J., Battista, S., Fedele, M., Trapasso, F., Zeki, K., Miano, M. P., De Nigris, F., Casalino, L., Curcio, F., Santoro, M., and Fusco, A. 1997. Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression. Oncogene. 16:1987-1994.
165. Voboril, R., and Weberova-Voborilova, J. 2006. Constitutive NF-kappaB activity in colorectal cancer cells: impact on radiation-induced NF-kappaB activity, radiosensitivity, and apoptosis. Neoplasma 6:518-523.
166. Wang, T., Wei, J., Qian, X., Ding, Y., Yu, L., and Liu, B. 2008. Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells. Cancer Lett. 2:214-22.
167. Wang, W., Abbruzzese, J. L., Evans, D. B., Larry, L, Cleary. K. R., and Chiao, P. J. 1999. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin. Cancer Res. 1:119-127.
168. Wang, W., Luo, H. S., and Yu, B. P. 2004. Expression of NF-kappaB and human telomerase reverse transcriptase in gastric cancer and precancerous lesions. World J. Gastroenterol. 2:177-181.
169. Yamamoto, K., Arakawa, T., Ueda, N., and Yamamoto, S. 1995. Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J. Biol. Chem. 270:31315-31320.
170. Yamamoto, S., Yamamoto, K., Kurobe, H., Yamashita, R., Yamaguchi, H., and Ueda, N. 1998. Transcriptional regulation of fatty acid cyclooxygenases-1 and -2. Int. J. Tissue React. 20:17-22.
171. Yang J., and Richmond A. 2001. Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. Cancer Res. 12:4901-4909.
172. Yeh, P. Y., Chuang, S. E., Yeh, K. H., Song, Y. C., Ea, C. K., and Cheng, A. L. 2002. Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation. Biochem. Pharmacol. 63:1423-1430.
173. Yu, H. G., Yu, L. L., Yang, Y., Luo, H. S., Yu, J. P., Meier, J. J., Schrader, H., Bastian, A., Schmidt, W. E., and Schmitz, F. 2003. Increased expression of RelA/nuclear factor-kappa B protein correlates with colorectal tumorigenesis. Oncology. 65:37-45.
174. Yuan, L., Choi, K., Khosla, C., Zheng, X., Higashikubo, R., Chicoine, M. R., and Rich, K. M. 2005. Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas. Mol. Cancer Ther. 4:1293-1302.
175. Zaffaroni, N., and Daidone, M. G. 2002. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist. Updat. 5:65-72.
176. Zatelli, M. C., Luchin, A., Tagliati, F., Leoni, S., Piccin, D., Bondanelli, M., Rossi, R., and Degli Uberti, E. C. 2007. Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression. Endocr. Relat. Cancer. 14:1029-1038.
177. Zhang, F., Altorki, N. K., Mestre, J. R., Subbaramaiah, K., and Dannenberg, A. J. 1999. Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis. 20:445-451.